Evidence map›Paper›PMID 26184976›Full record

ArticleApplied microbiology and biotechnology2015

Enhancing the selective extracellular location of a recombinant E. coli domain antibody by management of fermentation conditions.

Ioannis Voulgaris, Gary Finka, Mark Uden, Mike Hoare

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Secretion of recombinant proteins fromEngineering in life sciences · 2018
    Review
  7. Article
  8. How to trigger periplasmic release in recombinantEngineering in life sciences · 2017
    Article
  9. Article
  10. Improving of pelB-Secreted MPT64 protein released byJournal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Ioannis VoulgarisBioPharm R&D, BioPharm Process Research, GlaxoSmithKline R&D, Stevenage, SG1 2NY, UK.
Gary FinkaBioPharm R&D, BioPharm Process Research, GlaxoSmithKline R&D, Stevenage, SG1 2NY, UK.
Mark UdenBioPharm R&D, BioPharm Process Research, GlaxoSmithKline R&D, Stevenage, SG1 2NY, UK.
Mike HoareThe Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, London, WC1H 0AH, UK. m.hoare@ucl.ac.uk.
Biochemical Society · GBBioPharm (United Kingdom) · GBGlaxoSmithKline (United Kingdom) · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preparation of a recombinant protein using Escherichia coli often involves a challenging primary recovery sequence. This is due to the inability to secrete the protein to the extracellular space without a significant degree of cell lysis. This results in the release of nucleic acids, leading to a high viscosity, difficulty to clarify, broth and also to contamination with cell materials such as lipopolysaccharides and host cell proteins. In this paper, we present different fermentation strategies to facilitate the recovery of a V H domain antibody (13.1 kDa) by directing it selectively to the extracellular space and changing the balance between domain antibody to nucleic acid release. The manipulation of the cell growth rate in order to increase the outer cell membrane permeability gave a small ~1.5-fold improvement in released domain antibody to nucleic acid ratio without overall loss of yield. The introduction during fermentation of release agents such as EDTA gave no improvement in the ratio of released domain antibody to nucleic acid and a loss of overall productivity. The use of polyethyleneimine (PEI) during fermentation was with the aim to (a) permeabilise the outer bacterial membrane to release selectively domain antibody and (b) remove selectively by precipitation nucleic acids released during cell lysis. This strategy resulted in up to ~4-fold increase in the ratio of domain antibody to soluble nucleic acid with no reduction in domain antibody overall titre. In addition, a reduction in host cell protein contamination was achieved and there was no increase in endotoxin levels. Similar results were demonstrated with a range of other antibody products prepared in E. coli.

Indexed as

AntibodiesCulture MediaEscherichia coliFermentationPermeabilityPolyethyleneimineProtein TransportRecombinant ProteinsAntibodiesCulture MediaPolyethyleneimineRecombinant ProteinsDomain antibodyE. coliFermentationPeriplasmic releasePolyethyleneimine

Identifiers

PMID26184976
PMCPMC4768232
OpenAlexW904151909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.